All In Biotech

Drug Trial Radar · NCT03267940

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Feb 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

85

Actual

Start

Oct 2, 2017

Primary completion

Nov 11, 2019

Study completion Nov 11, 2019

Sponsor

Lead sponsor
Halozyme TherapeuticsIndustry
Sponsor type
Industry
First posted
Aug 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to assess the safety and tolerability of (1) PEGPH20 in combination with CIS and GEM (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and atezolizumab (PEGCISGEMATEZO) compared with (3) cisplatin and gemcitabine (CISGEM).

Conditions

  • Cholangiocarcinoma Non-resectable
  • Cholangiocarcinoma, Intrahepatic
  • Cholangiocarcinoma, Extrahepatic
  • Gallbladder Adenocarcinoma

Interventions

  • PEGPH20Drug

    PEGPH20 will be administered as per the schedule specified in the respective arms.

  • CISDrug

    CIS will be administered as per the schedule specified in the respective arms.

  • GEMDrug

    GEM will be administered as per the schedule specified in the respective arms.

  • AtezolizumabDrug

    Atezolizumab will be administered as per the schedule specified in the respective arms.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Run-in Portion: Number of Participants With Adverse Events (AEs)Time frame: From first exposure to study drug through 30 days after the end of treatment visit (maximum exposure: 508 days)
  2. Run-in Portion: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters (Hematology and Blood Chemistry)Time frame: From first exposure to study drug through the end of treatment visit (maximum exposure: 508 days)
  3. Run-in Portion: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) and Vital SignsTime frame: From first exposure to study drug through the end of treatment visit (maximum exposure: 508 days)
  4. Run-in Portion: Number of Participants With AEs Leading to Dose Reduction or Interruption of Any Study MedicationTime frame: From first exposure to study drug through the end of treatment visit (maximum exposure: 508 days)
  5. Expansion Portion: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1: Percentage of Participants With Objective ResponseTime frame: From date of randomization until the date of first documented progression of disease or date of death from any cause, whichever came first (maximum exposure: 421 days)

Locations

36 sites in 3 countries. Site status is shown where the registry gives one.

  • Mayo Clinic of Arizona

    Phoenix, Arizona

  • University of Arizona

    Tucson, Arizona

  • City of Hope

    Duarte, California

  • Scripps

    La Jolla, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • University of California Irvine Division of Hematology-Oncology, Department of Medicine UC Irvine Health

    Orange, California

  • UC Davis

    Sacramento, California

  • UCLA - David Geffen School of Medicine

    Santa Monica, California

  • The Oncology Institute of Hope and Innovation

    Whittier, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Lombardi Cancer Center, Georgetown University

    Washington D.C., District of Columbia

  • Johns Hopkins

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Mount Sinai

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Duke Cancer Institute

    Durham, North Carolina

  • Gabrail Cancer Center

    Canton, Ohio

  • University of Pittsburgh Cancer Institute

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • MD Anderson Cancer Center

    Houston, Texas

  • UT Health Cancer Center

    San Antonio, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Virginia Mason

    Seattle, Washington

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Froedtert Hospital And Medical College

    Milwaukee, Wisconsin

  • Samsung Medical Center

    Seoul, Gangnam-gu, South Korea

  • Korea University Guro Hospital

    Seoul, Guro-gu, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Seoul National University Hospital

    Seoul, Jongno-gu, South Korea

  • The Catholic University of Korea Seoul St. Mary's Hospital

    Seoul, Seocho-gu, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, Seodaemun-Gu, South Korea

  • Asan Medical Center

    Seoul, Songpa-gu, South Korea

  • Prince of Songkla University

    Hat Yai, Changwat Songkhla, Thailand

  • Maharaj Nakorn Chiang Mai Hospital

    Chiang Mai, Muang, Thailand

  • King Chulalongkorn Memorial Hospital

    Bangkok, Patumwan, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.